Signal Genetics Announces Master Service Agreement With Major Biopharmaceutical Partner

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. DAL

Go back to Signal Genetics Announces Master Service Agreement With Major Biopharmaceutical Partner

Signal Genetics (SGNL) Signs Second MSA with for MyPRS; Success Could Lead to Larger Phase 3s

September 23, 2015 2:40 PM EDT

Chardan Capital affirms its Buy rating and $2.75 price target on Signal Genetics (Nasdaq: SGNL) after the company announced the signing of a... More

Signal Genetics (SGNL) and Major Biopharma Partner Sign Master Service Agreement

September 23, 2015 7:03 AM EDT

Signal Genetics (Nasdaq: SGNL) announced the signing of a Master Service Agreement (MSA) with a leading biopharmaceutical company. The first two projects under this MSA will deploy Signal's proprietary MyPRS® test to inform the clinical stage development program of a novel treatment including potential combination therapies with current drugs for patients with multiple... More